Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

XBiotech Inc. - Common Stock (NQ:XBIT)

2.360 +0.050 (+2.16%)
Streaming Delayed Price Updated: 9:30 AM EST, Feb 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,538
Open 2.360
Bid (Size) 2.340 (1,000)
Ask (Size) 2.370 (100)
Prev. Close 2.310
Today's Range 2.360 - 2.360
52wk Range 2.090 - 3.620
Shares Outstanding 30,436,964
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
XBIT Investors Have Opportunity to Join XBiotech Inc. Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
News headline image
XBiotech Pauses Rheumatology program
Findings from recently completed Rheumatoid Arthritis Study raise questions 
From XBiotech Inc.
Via GlobeNewswire

Performance

YTD
-0.8%
-0.8%
1 Month
-6.7%
-6.7%
3 Month
-3.7%
-3.7%
6 Month
-20.0%
-20.0%
1 Year
-28.9%
-28.9%

More News

Read More
News headline image
XBIT Stock Earnings: XBiotech Reported Results for Q2 2024 ↗
Via InvestorPlace
News headline image
What's Going On With Small-Cap Cancer Focused XBiotech On Tuesday? ↗
Via Benzinga
News headline image
XBIT Stock Earnings: XBiotech Reported Results for Q1 2024 ↗
Via InvestorPlace
News headline image
XBIT Stock Earnings: XBiotech Reported Results for Q4 2023 ↗
Via InvestorPlace
News headline image
Stocks That Hit 52-Week Lows On Thursday ↗
Via Benzinga
News headline image
XBiotech Results from Randomized Double-Blinded Phase 1/2 Study Suggest Potential Breakthrough Treatment for Advanced Pancreatic Cancer
From XBiotech Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
Via Benzinga
News headline image
XBiotech to Begin Constructing New R&D Facility on its 48-acre Campus
From XBiotech Inc.
Via GlobeNewswire
News headline image
Dr. Alan Kivitz to Chair XBiotech’s Natrunix Program in Rheumatoid Arthritis
From XBiotech Inc.
Via GlobeNewswire
News headline image
XBiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke
From XBiotech Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
Via Benzinga
News headline image
XBiotech Announces Enrollment Completion of Phase II, Placebo Controlled, Multicenter Study for Natrunix in Pancreatic Cancer
From XBiotech Inc.
Via GlobeNewswire
News headline image
XBiotech Announces First Patient Begins Novel Natrunix Therapy in Phase II Rheumatoid Arthritis (RA) Clinical Trial
From XBiotech Inc.
Via GlobeNewswire
News headline image
FDA Authorizes Phase II Study for Natrunix in Rheumatoid Arthritis Patients
From XBiotech Inc.
Via GlobeNewswire
News headline image
Why Doximity Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗
Via Benzinga
News headline image
Dow Jumps Over 100 Points; US Housing Starts Rise In April ↗
Via Benzinga
News headline image
XBiotech Commences Tender Offer to Purchase up to $80,000,000 Worth of Its Shares
From XBiotech Inc.
Via GlobeNewswire
News headline image
XBiotech Announces First Subject Enrollment in Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke
From XBiotech Inc.
Via GlobeNewswire
News headline image
Stocks That Hit 52-Week Lows On Monday ↗
Via Benzinga
News headline image
XBiotech Announces First Patient Enrolled into the French National Cancer Institute (INCA) Sponsored Phase I/II/III Clinical Study for Natrunix™ Therapy for Colorectal Cancer
From XBiotech Inc.
Via GlobeNewswire
News headline image
Stocks That Hit 52-Week Lows On Thursday ↗
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Tuesday ↗
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Monday ↗
Via Benzinga

Frequently Asked Questions

Is XBiotech Inc. - Common Stock publicly traded?
Yes, XBiotech Inc. - Common Stock is publicly traded.
What exchange does XBiotech Inc. - Common Stock trade on?
XBiotech Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for XBiotech Inc. - Common Stock?
The ticker symbol for XBiotech Inc. - Common Stock is XBIT on the Nasdaq Stock Market
What is the current price of XBiotech Inc. - Common Stock?
The current price of XBiotech Inc. - Common Stock is 2.360
When was XBiotech Inc. - Common Stock last traded?
The last trade of XBiotech Inc. - Common Stock was at 02/10/26 09:30 AM ET
What is the market capitalization of XBiotech Inc. - Common Stock?
The market capitalization of XBiotech Inc. - Common Stock is 71.83M
How many shares of XBiotech Inc. - Common Stock are outstanding?
XBiotech Inc. - Common Stock has 72M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.